Fredun Pharmaceuticals Ltd
BSE:539730
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/B
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Valuation Scenarios
If P/B returns to its 3-Year Average (4.2), the stock would be worth ₹1 216.89 (40% downside from current price).
| Scenario | P/B Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 7 | ₹2 039.25 |
0%
|
| 3-Year Average | 4.2 | ₹1 216.89 |
-40%
|
| 5-Year Average | 5.2 | ₹1 509.93 |
-26%
|
| Industry Average | 3.6 | ₹1 041.54 |
-49%
|
| Country Average | 3.3 | ₹951.73 |
-53%
|
Forward P/B
Today’s price vs future total equity
Peer Comparison
| Market Cap | P/B | P/E | ||||
|---|---|---|---|---|---|---|
| IN |
|
Fredun Pharmaceuticals Ltd
BSE:539730
|
11.2B INR | 7 | 30.5 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
820.3B USD | 31.1 | 40 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
548.5B USD | 6.7 | 26.1 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 7.7 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
215.6B GBP | 5.9 | 27.9 | |
| CH |
|
Novartis AG
SIX:NOVN
|
218.9B CHF | 5.9 | 19.6 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
272.8B USD | 5.2 | 14.9 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | -58.7 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 6.1 | 11.5 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
152.3B USD | 1.7 | 19.4 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
116.3B USD | 6.3 | 16.6 |
Market Distribution
| Min | 0 |
| 30th Percentile | 2.1 |
| Median | 3.3 |
| 70th Percentile | 5.5 |
| Max | 4 699.1 |
Other Multiples
Fredun Pharmaceuticals Ltd
Glance View
Fredun Pharmaceuticals Ltd. engages in the manufacture and sale of pharmaceuticals, neutraceuticals, herbal and dietary supplements. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2016-03-17. The firm is primarily engaged in the business of pharmaceuticals and healthcare. The company operates through pharmaceutical formulation segment. The company offers a range of products, including antihypertensives, antidiabetic, antiretroviral drugs (ARVs) and narcotics. The company is also engaged in the manufacturing of dietary /herbal supplements, nutraceuticals, and other healthcare products along with animal healthcare products. The firm primarily exports its products to Africa, Southeast Asia, Commonwealth of Independent States (CIS) countries and Latin America.
